Effect of Dietary Macronutrient Composition
Effect of Dietary Macronutrient Composition on Liver Substrate Metabolism
調査の概要
詳細な説明
Obesity is a major factor driving the increased prevalence of hepatic steatosis in the US. However, little is known regarding the relationship between dietary intake and hepatic fat deposition or about the factors that promote loss of hepatic steatosis. Here, the investigators will determine how differences in dietary composition affect the development and regression of fatty liver. The investigators hypothesize that Hispanic subjects with metabolic syndrome will have higher liver fat synthesis rates compared to African American subjects.
Using detailed in vivo, serial measurements of fuel metabolism (GC/MS and NMR) fatty acid metabolism will be measured in the liver and periphery. This will be the first study in which these two methodologies are used together to assess both glucose and fatty acid metabolism in the same subjects. Subjects will be tested before and after a dietary weight-loss intervention producing 6% body weight loss over 5 months.
The specific aims are as follows:
AIM 1: Determine the contribution of peripheral and dietary fat to liver-TG in Hispanics and African Americans with metabolic syndrome.
Hypothesis: De novo lipogenesis will contribute to liver-TG in greater quantities compared to African Americans.
AIM 2: Determine the effects of low-CHO and low-fat diets on liver fat regression.
Hypothesis: Compared to a low-fat diet, a low-CHO diet will markedly decrease markers of inflammation coincident with greater improvements in insulin sensitivity as assessed by an intravenous glucose tolerance test.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Texas
-
Dallas、Texas、アメリカ、75390-9052
- Center for Human Nutrition
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Elevated serum ALT or metabolic syndrome
- African American or Hispanic
- Nondiabetic
- Men or women
- Smokers and nonsmokers
- Pre- and post-menopausal (+/- HRT)
- Stable body weight
- Age 20-65 years
- BMI between 25-45 kg/m2
Exclusion Criteria:
- Diabetes or Pregnancy
- Ethanol intake: males > 140 g/week, females > 70 g/week
- Chronic hepatitis B or chronic hepatitis C
- Hemochromatosis or Wilson's Disease
- Autoimmune hepatitis or primary biliary cirrhosis
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:階乗代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
他の:Hispanic subjects
Subjects will identify as Hispanic ethnicity.
|
The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months.
Fat will make up less than 30% of dietary energy.
The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period.
Carbohydrate will provide less than 40% of total dietary energy.
|
他の:African American subjects
Subjects will self-identify as African American in origin.
|
The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months.
Fat will make up less than 30% of dietary energy.
The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period.
Carbohydrate will provide less than 40% of total dietary energy.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
de novo lipogenesis
時間枠:Change from Baseline in fatty acid synthesis at 5 months
|
In vivo measurement is made of liver fatty acid synthesis using stable isotope administration and analysis of plasma samples by GS/MS
|
Change from Baseline in fatty acid synthesis at 5 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Dietary fatty acid clearance to liver
時間枠:Change from Baseline in dietary fat clearance at 5 months
|
Using a dietary stable isotope we will quantitate fat absorption and recycling of fat through the liver.
|
Change from Baseline in dietary fat clearance at 5 months
|
Adipose fatty acid flux
時間枠:Change from Baseline in adipose fat flux at 5 months
|
A stable isotope is infused and the rate of adipose fatty acid release is calculated after analyzing blood samples.
|
Change from Baseline in adipose fat flux at 5 months
|
協力者と研究者
捜査官
- 主任研究者:Elizabeth J Parks, PhD、UTSW Medical Center
出版物と役立つリンク
一般刊行物
- Shetty S, Ramos-Roman MA, Cho YR, Brown J, Plutzky J, Muise ES, Horton JD, Scherer PE, Parks EJ. Enhanced fatty acid flux triggered by adiponectin overexpression. Endocrinology. 2012 Jan;153(1):113-22. doi: 10.1210/en.2011-1339. Epub 2011 Nov 1.
- Ramos-Roman MA, Sweetman L, Valdez MJ, Parks EJ. Postprandial changes in plasma acylcarnitine concentrations as markers of fatty acid flux in overweight and obesity. Metabolism. 2012 Feb;61(2):202-12. doi: 10.1016/j.metabol.2011.06.008. Epub 2011 Aug 5.
- Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011 Dec 7;14(6):804-10. doi: 10.1016/j.cmet.2011.11.004.
- Satapati S, Kucejova B, Duarte JA, Fletcher JA, Reynolds L, Sunny NE, He T, Nair LA, Livingston KA, Fu X, Merritt ME, Sherry AD, Malloy CR, Shelton JM, Lambert J, Parks EJ, Corbin I, Magnuson MA, Browning JD, Burgess SC. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest. 2016 Apr 1;126(4):1605. doi: 10.1172/JCI86695. Epub 2016 Apr 1. No abstract available.
- Lee JJ, Lambert JE, Hovhannisyan Y, Ramos-Roman MA, Trombold JR, Wagner DA, Parks EJ. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am J Clin Nutr. 2015 Jan;101(1):34-43. doi: 10.3945/ajcn.114.092262. Epub 2014 Nov 19.
- Lambert JE, Parks EJ. Getting the label in: practical research strategies for tracing dietary fat. Int J Obes Suppl. 2012 Dec;2(Suppl 2):S43-50. doi: 10.1038/ijosup.2012.22. Epub 2012 Dec 11.
- Ramos-Roman MA, Lapidot SA, Phair RD, Parks EJ. Insulin activation of plasma nonesterified fatty acid uptake in metabolic syndrome. Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1799-808. doi: 10.1161/ATVBAHA.112.250019. Epub 2012 Jun 21.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 5RL-1DK081187
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Low-fat dietの臨床試験
-
Mondelēz International, Inc.KGK Science Inc.完了
-
Mitsubishi Tanabe Pharma Corporation完了再発寛解型多発性硬化症クロアチア, ブルガリア, チェコ共和国, イタリア, ロシア連邦, スペイン, イギリス, ドイツ, リトアニア, ポーランド, ベルギー, ハンガリー, セルビア, フィンランド, ウクライナ, スイス, カナダ, 七面鳥
-
Mitsubishi Tanabe Pharma Corporation完了
-
Mitsubishi Tanabe Pharma Corporation完了再発寛解型多発性硬化症ベルギー, ブルガリア, カナダ, クロアチア, チェコ共和国, フィンランド, ドイツ, ハンガリー, イタリア, リトアニア, ポーランド, ロシア連邦, セルビア, スペイン, 七面鳥, ウクライナ, イギリス
-
Pepperdine University募集